



Polymeric Nanovaccines for Immune Modulation

Guest Editors:

Dr. Saji Uthaman

Department of Chemical and
Biological Engineering, Iowa
State University, Ames, IA, USA

Prof. Dr. In-Kyu Park

Department of Biomedical
Sciences, Chonnam National
University Medical School, 160
Baekseo-ro, Gwangju 58128,
Korea

Deadline for manuscript
submissions:

closed (10 March 2022)

Message from the Guest Editors

Vaccination is one of the most effective ways to cure human diseases. With the advancements in science and technology, nanovaccines comprising nanoparticles that are either used as adjuvants or carriers has emerged as one of the most effective treatment strategies for health promotion and disease prevention. Nanovaccines are reported to be highly efficient in inducing humoral and cell-mediated immune responses and demonstrate high antigen loading, enhanced immunogenicity, and controlled antigen presentation. Polymers from the natural or synthetic route are often used for developing nanovaccines which could be easily internalized by antigen-presenting cells and exert immune modulations owing to the unique physiochemical properties of nanoparticles.

We are calling for manuscripts detailing natural and synthetic polymeric nanovaccines, anticancer nanovaccine delivery systems, immune modulating polymeric nanoparticles, etc. We sincerely hope this Special Issue serves as a platform for the exchange of the latest developments in the field of polymeric nano vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com